JP2020513730A - コンパニオンアニマルにおける細菌を調節する組成物及び方法 - Google Patents
コンパニオンアニマルにおける細菌を調節する組成物及び方法 Download PDFInfo
- Publication number
- JP2020513730A JP2020513730A JP2018561991A JP2018561991A JP2020513730A JP 2020513730 A JP2020513730 A JP 2020513730A JP 2018561991 A JP2018561991 A JP 2018561991A JP 2018561991 A JP2018561991 A JP 2018561991A JP 2020513730 A JP2020513730 A JP 2020513730A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- lactobacillus
- bifidobacterium
- metabolites
- clostridium perfringens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241001465754 Metazoa Species 0.000 title claims abstract description 98
- 241000894006 Bacteria Species 0.000 title claims abstract description 30
- 239000000203 mixture Substances 0.000 title claims description 151
- 238000000034 method Methods 0.000 title claims description 66
- 241000186660 Lactobacillus Species 0.000 claims abstract description 70
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 70
- 241000186000 Bifidobacterium Species 0.000 claims abstract description 69
- 241000193468 Clostridium perfringens Species 0.000 claims abstract description 68
- 239000002207 metabolite Substances 0.000 claims description 160
- 235000013305 food Nutrition 0.000 claims description 82
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims description 28
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 claims description 24
- 230000001965 increasing effect Effects 0.000 claims description 23
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 claims description 21
- WWNNZCOKKKDOPX-UHFFFAOYSA-N N-methylnicotinate Chemical compound C[N+]1=CC=CC(C([O-])=O)=C1 WWNNZCOKKKDOPX-UHFFFAOYSA-N 0.000 claims description 20
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 17
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 17
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 17
- 235000000431 campesterol Nutrition 0.000 claims description 17
- AHANXAKGNAKFSK-PDBXOOCHSA-N all-cis-icosa-11,14,17-trienoic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCCCC(O)=O AHANXAKGNAKFSK-PDBXOOCHSA-N 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- WHBMMWSBFZVSSR-UHFFFAOYSA-N R3HBA Natural products CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims description 13
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims description 12
- 235000021294 Docosapentaenoic acid Nutrition 0.000 claims description 12
- 108090000623 proteins and genes Proteins 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 10
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 10
- 235000018102 proteins Nutrition 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- BITHHVVYSMSWAG-KTKRTIGZSA-N (11Z)-icos-11-enoic acid Chemical compound CCCCCCCC\C=C/CCCCCCCCCC(O)=O BITHHVVYSMSWAG-KTKRTIGZSA-N 0.000 claims description 7
- RBNPOMFGQQGHHO-UHFFFAOYSA-N -2,3-Dihydroxypropanoic acid Natural products OCC(O)C(O)=O RBNPOMFGQQGHHO-UHFFFAOYSA-N 0.000 claims description 7
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 7
- RHCPKKNRWFXMAT-RRWYKFPJSA-N 3alpha,12alpha-dihydroxy-7-oxo-5beta-cholanic acid Chemical compound C1C[C@@H](O)C[C@H]2CC(=O)[C@H]3[C@@H]4CC[C@H]([C@@H](CCC(O)=O)C)[C@@]4(C)[C@@H](O)C[C@@H]3[C@]21C RHCPKKNRWFXMAT-RRWYKFPJSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- RBNPOMFGQQGHHO-UWTATZPHSA-N D-glyceric acid Chemical compound OC[C@@H](O)C(O)=O RBNPOMFGQQGHHO-UWTATZPHSA-N 0.000 claims description 7
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- -1 adrenate (22: 4n6) Chemical compound 0.000 claims description 7
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 claims description 7
- 235000020661 alpha-linolenic acid Nutrition 0.000 claims description 7
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 7
- 229940108623 eicosenoic acid Drugs 0.000 claims description 7
- BITHHVVYSMSWAG-UHFFFAOYSA-N eicosenoic acid Natural products CCCCCCCCC=CCCCCCCCCCC(O)=O BITHHVVYSMSWAG-UHFFFAOYSA-N 0.000 claims description 7
- 229960004488 linolenic acid Drugs 0.000 claims description 7
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- WHBMMWSBFZVSSR-UHFFFAOYSA-M 3-hydroxybutyrate Chemical compound CC(O)CC([O-])=O WHBMMWSBFZVSSR-UHFFFAOYSA-M 0.000 claims description 6
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 6
- RWKUXQNLWDTSLO-GWQJGLRPSA-N N-hexadecanoylsphingosine-1-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)N[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)[C@H](O)\C=C\CCCCCCCCCCCCC RWKUXQNLWDTSLO-GWQJGLRPSA-N 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 6
- 229960002997 dehydrocholic acid Drugs 0.000 claims description 6
- 230000004060 metabolic process Effects 0.000 claims description 6
- 229940055726 pantothenic acid Drugs 0.000 claims description 6
- 235000019161 pantothenic acid Nutrition 0.000 claims description 6
- 239000011713 pantothenic acid Substances 0.000 claims description 6
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 5
- RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 claims description 5
- OEKUSRBIIZNLHZ-YXRVOZSUSA-N (4r)-4-[(5r,7r,8r,9s,10s,12s,13r,14s,17s)-7,12-dihydroxy-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid Chemical compound C([C@H]1C[C@H]2O)C(=O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 OEKUSRBIIZNLHZ-YXRVOZSUSA-N 0.000 claims description 5
- AXPAUZGVNGEWJD-UHFFFAOYSA-N 2-methylhexadecanoic acid Chemical compound CCCCCCCCCCCCCCC(C)C(O)=O AXPAUZGVNGEWJD-UHFFFAOYSA-N 0.000 claims description 5
- OYXZMSRRJOYLLO-UHFFFAOYSA-N 7alpha-Hydroxycholesterol Natural products OC1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 OYXZMSRRJOYLLO-UHFFFAOYSA-N 0.000 claims description 5
- OYXZMSRRJOYLLO-RVOWOUOISA-N 7alpha-hydroxycholesterol Chemical compound C([C@H]1O)=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 OYXZMSRRJOYLLO-RVOWOUOISA-N 0.000 claims description 5
- 239000004380 Cholic acid Substances 0.000 claims description 5
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 5
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 claims description 5
- 235000021314 Palmitic acid Nutrition 0.000 claims description 5
- 235000021355 Stearic acid Nutrition 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 5
- RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 claims description 5
- 229960001091 chenodeoxycholic acid Drugs 0.000 claims description 5
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 5
- 235000019416 cholic acid Nutrition 0.000 claims description 5
- 229960002471 cholic acid Drugs 0.000 claims description 5
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 5
- 239000003925 fat Substances 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 239000000835 fiber Substances 0.000 claims description 5
- SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 5
- IIUXHTGBZYEGHI-UHFFFAOYSA-N isoheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCC(O)=O IIUXHTGBZYEGHI-UHFFFAOYSA-N 0.000 claims description 5
- 235000020778 linoleic acid Nutrition 0.000 claims description 5
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 claims description 5
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 5
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 5
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 5
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 5
- 239000008117 stearic acid Substances 0.000 claims description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 4
- 230000007407 health benefit Effects 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- 230000004584 weight gain Effects 0.000 claims description 3
- 235000019786 weight gain Nutrition 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010017533 Fungal infection Diseases 0.000 claims description 2
- 208000012868 Overgrowth Diseases 0.000 claims description 2
- 238000010521 absorption reaction Methods 0.000 claims description 2
- 230000002411 adverse Effects 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000008859 change Effects 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 230000001079 digestive effect Effects 0.000 claims description 2
- 230000036074 healthy skin Effects 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- YNOWULSFLVIUDH-UHFFFAOYSA-O 3-dehydrocarnitinium Chemical compound C[N+](C)(C)CC(=O)CC(O)=O YNOWULSFLVIUDH-UHFFFAOYSA-O 0.000 claims 8
- 241000193403 Clostridium Species 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 229960001238 methylnicotinate Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 34
- 235000005911 diet Nutrition 0.000 abstract description 17
- 230000037213 diet Effects 0.000 abstract description 17
- 238000010586 diagram Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 37
- 239000002243 precursor Substances 0.000 description 22
- 235000013372 meat Nutrition 0.000 description 14
- 241000282472 Canis lupus familiaris Species 0.000 description 13
- 239000000047 product Substances 0.000 description 9
- 230000008569 process Effects 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000006041 probiotic Substances 0.000 description 7
- 235000018291 probiotics Nutrition 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000001276 controlling effect Effects 0.000 description 6
- 230000037406 food intake Effects 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 241000282326 Felis catus Species 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 240000008042 Zea mays Species 0.000 description 4
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 4
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 4
- 235000005822 corn Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 238000010200 validation analysis Methods 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- YNOWULSFLVIUDH-UHFFFAOYSA-N 3-dehydrocarnitine Chemical compound C[N+](C)(C)CC(=O)CC([O-])=O YNOWULSFLVIUDH-UHFFFAOYSA-N 0.000 description 3
- 108010068370 Glutens Proteins 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- 239000003086 colorant Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 238000004817 gas chromatography Methods 0.000 description 3
- 235000021312 gluten Nutrition 0.000 description 3
- 238000004811 liquid chromatography Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 238000002705 metabolomic analysis Methods 0.000 description 3
- 230000001431 metabolomic effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000000050 nutritive effect Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 2
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 2
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 235000015177 dried meat Nutrition 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002550 fecal effect Effects 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 235000015277 pork Nutrition 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 235000013311 vegetables Nutrition 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- UBVSIAHUTXHQTD-UHFFFAOYSA-N 2-n-(4-bromophenyl)-1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(NC=2C=CC(Br)=CC=2)=N1 UBVSIAHUTXHQTD-UHFFFAOYSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- 241000881711 Acipenser sturio Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- DHHFDKNIEVKVKS-FMOSSLLZSA-N Betanin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC(C(=C1)O)=CC(C[C@H]2C([O-])=O)=C1[N+]2=C\C=C\1C=C(C(O)=O)N[C@H](C(O)=O)C/1 DHHFDKNIEVKVKS-FMOSSLLZSA-N 0.000 description 1
- DHHFDKNIEVKVKS-MVUYWVKGSA-N Betanin Natural products O=C(O)[C@@H]1NC(C(=O)O)=C/C(=C\C=[N+]/2\[C@@H](C(=O)[O-])Cc3c\2cc(O)c(O[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O2)c3)/C1 DHHFDKNIEVKVKS-MVUYWVKGSA-N 0.000 description 1
- 244000017106 Bixa orellana Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 240000004160 Capsicum annuum Species 0.000 description 1
- 235000008534 Capsicum annuum var annuum Nutrition 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 244000124209 Crocus sativus Species 0.000 description 1
- 235000015655 Crocus sativus Nutrition 0.000 description 1
- 244000163122 Curcuma domestica Species 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 240000002390 Pandanus odoratissimus Species 0.000 description 1
- 108010084695 Pea Proteins Proteins 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 240000009164 Petroselinum crispum Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 244000151637 Sambucus canadensis Species 0.000 description 1
- 235000018735 Sambucus canadensis Nutrition 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000012665 annatto Nutrition 0.000 description 1
- 239000010362 annatto Substances 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 235000012677 beetroot red Nutrition 0.000 description 1
- 239000001654 beetroot red Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000002185 betanin Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 235000007123 blue elder Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 239000000828 canola oil Substances 0.000 description 1
- 235000019519 canola oil Nutrition 0.000 description 1
- 239000001511 capsicum annuum Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000012730 carminic acid Nutrition 0.000 description 1
- 239000004106 carminic acid Substances 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- OIQPTROHQCGFEF-UHFFFAOYSA-L chembl1371409 Chemical compound [Na+].[Na+].OC1=CC=C2C=C(S([O-])(=O)=O)C=CC2=C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 OIQPTROHQCGFEF-UHFFFAOYSA-L 0.000 description 1
- CEZCCHQBSQPRMU-UHFFFAOYSA-L chembl174821 Chemical compound [Na+].[Na+].COC1=CC(S([O-])(=O)=O)=C(C)C=C1N=NC1=C(O)C=CC2=CC(S([O-])(=O)=O)=CC=C12 CEZCCHQBSQPRMU-UHFFFAOYSA-L 0.000 description 1
- 229930002875 chlorophyll Natural products 0.000 description 1
- 235000019804 chlorophyll Nutrition 0.000 description 1
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 229940080423 cochineal Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 230000003467 diminishing effect Effects 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000007124 elderberry Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 235000012732 erythrosine Nutrition 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000000576 food coloring agent Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 235000020993 ground meat Nutrition 0.000 description 1
- 230000008821 health effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 235000019702 pea protein Nutrition 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 235000011197 perejil Nutrition 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000000529 probiotic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000013974 saffron Nutrition 0.000 description 1
- 239000004248 saffron Substances 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 235000010268 sodium methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004290 sodium methyl p-hydroxybenzoate Substances 0.000 description 1
- PESXGULMKCKJCC-UHFFFAOYSA-M sodium;4-methoxycarbonylphenolate Chemical compound [Na+].COC(=O)C1=CC=C([O-])C=C1 PESXGULMKCKJCC-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229940001941 soy protein Drugs 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003760 tallow Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 239000011135 tin Substances 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- UJMBCXLDXJUMFB-UHFFFAOYSA-K trisodium;5-oxo-1-(4-sulfonatophenyl)-4-[(4-sulfonatophenyl)diazenyl]-4h-pyrazole-3-carboxylate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)C1=NN(C=2C=CC(=CC=2)S([O-])(=O)=O)C(=O)C1N=NC1=CC=C(S([O-])(=O)=O)C=C1 UJMBCXLDXJUMFB-UHFFFAOYSA-K 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/111—Aromatic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/116—Heterocyclic compounds
- A23K20/121—Heterocyclic compounds containing oxygen or sulfur as hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/163—Sugars; Polysaccharides
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/42—Dry feed
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
- A23K50/48—Moist feed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Animal Husbandry (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Fodder In General (AREA)
- Feed For Specific Animals (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
本出願は、2016年12月15日に出願された米国仮出願第62/434,560号の優先権を主張するものであり、この開示の全体は本参照により本明細書に組み込まれる。
本開示の一態様では、ペットフード組成物は、タンパク質と、炭水化物と、脂肪と、繊維と、コンパニオンアニマルにおけるビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量を調節するための代謝産物と、を含み得る。一実施形態では、ペットフード組成物は、コンパニオンアニマルにおける、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量の増加を提供し得る。
[0065]各実施例は、以下の研究から得られた。
クロストリジウム・パーフリンジェンスとの代謝産物相関を、血漿メタボロミクスに基づいて決定した(表2)。これによって、クロストリジウム・パーフリンジェンスに正又は負のいずれかの影響を及ぼし得る化合物の予測モデルが提供された。これらの化合物を異なる濃度で給与し(食餌B対食餌A;表3)、クロストリジウム・パーフリンジェンスの変化(表4)に注目し、検証モデルとして供した。2つの異なる食餌の代謝産物組成を決定して、特定の化合物の相対的なレベルを特定した。モデルによって検証されたものを表5に示す。
ラクトバシラスとの代謝産物相関を、血漿メタボロミクスに基づいて決定した(表6)。これによって、ラクトバシラスに正又は負のいずれかの影響を及ぼし得る化合物の予測モデルが提供された。これらの化合物を異なる濃度で給与し(食餌B対食餌A;表7)、ラクトバシラスの変化(表8)に注目し、検証モデルとして供した。2つの異なる食餌の代謝産物組成を決定して、特定の化合物の相対的なレベルを特定した。モデルによって検証された化合物を表9に示す。
ビフィドバクテリウムとの代謝産物相関を、血漿メタボロミクスに基づいて決定した(表10)。これによって、ビフィドバクテリウムに正又は負のいずれかの影響を及ぼし得る化合物の予測モデルが提供された。これらの化合物を異なる濃度で給与し(食餌B対食餌A;表11)、ビフィドバクテリウムの変化(表12)に注目し、検証モデルとして供した。特定の化合物の相対的なレベルを特定するために、2つの異なる食餌の代謝産物組成を決定した。モデルによって検証された化合物を表13に示す。
Claims (20)
- ペットフード組成物であって、
タンパク質、炭水化物、脂肪、繊維、及び
コンパニオンアニマルにおけるビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスの量を個々に調節するための少なくとも6つの別個の代謝産物を含み、
ビフィドバクテリウムを調節する前記代謝産物が、カンペステロール、7−ケトデオキシコール酸、3−(4−ヒドロキシフェニル)プロピオン酸、3−デヒドロカルニチン、12−デヒドロコール酸、X−17314、X−15461、ケノデオキシコール酸、3−デヒドロコール酸、コール酸、15−メチルパルミチン酸(2−メチルパルミチン酸の同重体)及びこれらの混合物からなる群から選択され;
ラクトバシラスを調節する前記代謝産物が、X−15461、3−フェニルプロピオン酸(ヒドロシンナメート)、3−(4−ヒドロキシフェニル)プロピオン酸、マンニトール、カンペステロール、インドールアセテート、3−デヒドロカルニチン、X−11378及びこれらの混合物からなる群から選択され;
クロストリジウム・パーフリンジェンスを調節する前記代謝産物が、ジホモリノール酸(20:2n6)、アラキドン酸(20:4n6)、アドレナート(22:4n6)、マンノース、3−ヒドロキシブチレート(BHBA)、トリゴネリン(N’−ニコチン酸メチル)、エイコセン酸(20:1n9又は11)、ドコサペンタエン酸(n3 DPA;22:5n3)、パルミトイルスフィンゴミエリン、グリセリン酸、リノレン酸[α又はγ;(18:3n3又は6)]、ジホモリノレン酸(20:3n3又はn6)、X−11378、X−17010、7−α−ヒドロキシコレステロール、ステアリン酸(18:0)、パルミチン酸(16:0)、グリコール酸(ヒドロキシアセテート)、スタキドリン、X−12450、X−09789、カンペステロール、パントテン酸、リノール酸(18:2n6)、ドコサペンタエン酸(n6 DPA;22:5n6)、X−11412、X−17185、フェニルアラニン及びこれらの混合物からなる群から選択され;及び
前記ペットフード組成物が、前記コンパニオンアニマルに前記ペットフードを投与する際に、前記コンパニオンアニマルにおけるビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量において少なくとも5%の増加又は少なくとも5%の減少を提供する、ペットフード組成物。 - 前記組成物が、コンパニオンアニマルにおける、ビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスの各々1つを調節するための少なくとも3つの別個の代謝産物を含む少なくとも9つの別個の代謝産物を含む、請求項1に記載のペットフード組成物。
- 前記組成物が、コンパニオンアニマルにおける、ビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスの各々1つを調節するための少なくとも4つの別個の代謝産物を含む少なくとも12の別個の代謝産物を含む、請求項1に記載のペットフード組成物。
- ビフィドバクテリウムを調節する前記代謝産物が、カンペステロール、7−ケトデオキシコール酸、3−(4−ヒドロキシフェニル)プロピオン酸、3−デヒドロカルニチン、12−デヒドロコール酸、及びこれらの混合物からなる群から選択される、請求項1に記載のペットフード組成物。
- ラクトバシラスを調節する前記代謝産物が、X−15461、3−フェニルプロピオン酸(ヒドロシンナメート)、3−(4−ヒドロキシフェニル)プロピオン酸、マンニトール、及びこれらの混合物からなる群から選択される、請求項1に記載のペットフード組成物。
- クロストリジウム・パーフリンジェンスを調節する前記代謝産物が、ジホモリノール酸(20:2n6)、アラキドン酸(20:4n6)、アドレナート(22:4n6)、マンノース、3−ヒドロキシブチレート(BHBA)、トリゴネリン(N’−ニコチン酸メチル)、エイコセン酸(20:1n9又は11)、ドコサペンタエン酸(n3 DPA;22:5n3)、パルミトイルスフィンゴミエリン、グリセリン酸、リノレン酸[α又はγ;(18:3n3又は6)]、ジホモリノレン酸(20:3n3又はn6)、X−11378、X−17010、及びこれらの混合物からなる群から選択される、請求項1に記載のペットフード組成物。
- 前記ペットフード組成物が、前記コンパニオンアニマルにおける、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量において、少なくとも10%の増加を提供する、請求項1に記載のペットフード組成物。
- 前記ペットフード組成物が、前記コンパニオンアニマルにおける、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量において、少なくとも10%の減少を提供する、請求項1に記載のペットフード組成物。
- コンパニオンアニマルにおけるビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量を調節する方法であって、
タンパク質と、炭水化物と、脂肪と、繊維と、前記コンパニオンアニマルにおけるビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量を調節するための少なくとも3つの別個の代謝産物と、を含む、ペットフード組成物を前記コンパニオンアニマルに投与するステップを含み;
ビフィドバクテリウムを調節する前記代謝産物が、カンペステロール、7−ケトデオキシコール酸、3−(4−ヒドロキシフェニル)プロピオン酸、3−デヒドロカルニチン、12−デヒドロコール酸、X−17314、X−15461、ケノデオキシコール酸、3−デヒドロコール酸、コール酸、15−メチルパルミチン酸(2−メチルパルミチン酸の同重体)及びこれらの混合物からなる群から選択され;
ラクトバシラスを調節する前記代謝産物が、X−15461、3−フェニルプロピオン酸(ヒドロシンナメート)、3−(4−ヒドロキシフェニル)プロピオン酸、マンニトール、カンペステロール、インドールアセテート、3−デヒドロカルニチン、X−11378及びこれらの混合物からなる群から選択され;
クロストリジウム・パーフリンジェンスを調節する前記代謝産物が、ジホモリノール酸(20:2n6)、アラキドン酸(20:4n6)、アドレナート(22:4n6)、マンノース、3−ヒドロキシブチレート(BHBA)、トリゴネリン(N’−ニコチン酸メチル)、エイコセン酸(20:1n9又は11)、ドコサペンタエン酸(n3 DPA;22:5n3)、パルミトイルスフィンゴミエリン、グリセリン酸、リノレン酸[α又はγ;(18:3n3又は6)]、ジホモリノレン酸(20:3n3又はn6)、X−11378、X−17010、7−α−ヒドロキシコレステロール、ステアリン酸(18:0)、パルミチン酸(16:0)、グリコール酸(ヒドロキシアセテート)、スタキドリン、X−12450、X−09789、カンペステロール、パントテン酸、リノール酸(18:2n6)、ドコサペンタエン酸(n6 DPA;22:5n6)、X−11412、X−17185、フェニルアラニン及びこれらの混合物からなる群から選択される、方法。 - 前記組成物が、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つを調節する少なくとも4つの別個の代謝産物を含む、請求項9に記載の方法。
- 前記組成物が、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つを調節する少なくとも5つの別個の代謝産物を含む、請求項9に記載の方法。
- 前記方法が、ビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスからなる群から選択される少なくとも2つの細菌を調節し、前記組成物が、少なくとも6つの別個の代謝産物、少なくとも2つの細菌の各々を調節するための3つの別個の代謝産物を含む、請求項9に記載の方法。
- 前記方法が、ビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスを調節し、前記組成物が、少なくとも9つの別個の代謝産物、ビフィドバクテリウム、ラクトバシラス、及びクロストリジウム・パーフリンジェンスの各々を調節するための3つの別個の代謝産物を含む、請求項9に記載の方法。
- 前記ペットフード組成物が、前記コンパニオンアニマルにおける、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量において、少なくとも5%の増加又は少なくとも5%の減少を提供する、請求項9に記載の方法。
- 前記投与が、規則的投与である、請求項9に記載の方法。
- 前記調節が、以下の健康上の利益:体重増加、飼料要求率の増加、死亡率の低下、消化障害の減少、過敏性腸症候群の緩和、クローン病の緩和、細菌過剰繁殖の低下、食物消化の増加、ラクトース代謝の増加、抗生物質の悪影響の減少、健康な皮膚、酵母感染の減少、栄養素の吸収の増加、又は免疫系の増加、のうちの1つを提供する、請求項9に記載の方法。
- コンパニオンアニマルにおけるビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つの量の変化を測定する方法であって、
前記コンパニオンアニマルの血清サンプルを得るステップと、
ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つを調節する前記血清サンプルから少なくとも3つの別個の代謝産物の濃度を測定するステップと、
前記代謝産物濃度と、同程度のコンパニオンアニマルの各代謝産物の平均代謝産物濃度とを比較した後、前記代謝産物濃度が前記平均代謝産物濃度と異なる場合、ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスが変化したとして判定するステップと、を含み、
ビフィドバクテリウムを調節する前記代謝産物が、カンペステロール、7−ケトデオキシコール酸、3−(4−ヒドロキシフェニル)プロピオン酸、3−デヒドロカルニチン、12−デヒドロコール酸、X−17314、X−15461、ケノデオキシコール酸、3−デヒドロコール酸、コール酸、15−メチルパルミチン酸(2−メチルパルミチン酸の同重体)及びこれらの混合物からなる群から選択され;
ラクトバシラスを調節する前記代謝産物が、X−15461、3−フェニルプロピオン酸(ヒドロシンナメート)、3−(4−ヒドロキシフェニル)プロピオン酸、マンニトール、カンペステロール、インドールアセテート、3−デヒドロカルニチン、X−11378及びこれらの混合物からなる群から選択され;
クロストリジウム・パーフリンジェンスを調節する前記代謝産物が、ジホモリノール酸(20:2n6)、アラキドン酸(20:4n6)、アドレナート(22:4n6)、マンノース、3−ヒドロキシブチレート(BHBA)、トリゴネリン(N’−ニコチン酸メチル)、エイコセン酸(20:1n9又は11)、ドコサペンタエン酸(n3 DPA;22:5n3)、パルミトイルスフィンゴミエリン、グリセリン酸、リノレン酸[α又はγ;(18:3n3又は6)]、ジホモリノレン酸(20:3n3又はn6)、X−11378、X−17010、7−α−ヒドロキシコレステロール、ステアリン酸(18:0)、パルミチン酸(16:0)、グリコール酸(ヒドロキシアセテート)、スタキドリン、X−12450、X−09789、カンペステロール、パントテン酸、リノール酸(18:2n6)、ドコサペンタエン酸(n6 DPA;22:5n6)、X−11412、X−17185、フェニルアラニン及びこれらの混合物からなる群から選択される、方法。 - ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つを調節するための少なくとも4つの別個の代謝産物の濃度を測定するステップを含む、請求項17に記載の方法。
- ビフィドバクテリウム、ラクトバシラス、又はクロストリジウム・パーフリンジェンスのうちの少なくとも1つを調節するための少なくとも5つの別個の代謝産物の濃度を測定するステップを含む、請求項17に記載の方法。
- ビフィドバクテリウムを調節する前記代謝産物が、カンペステロール、7−ケトデオキシコール酸、3−(4−ヒドロキシフェニル)プロピオン酸、3−デヒドロカルニチン、12−デヒドロコール酸、及びこれらの混合物からなる群から選択され、
ラクトバシラスを調節する前記代謝産物が、X−15461、3−フェニルプロピオン酸(ヒドロシンナメート)、3−(4−ヒドロキシフェニル)プロピオン酸、マンニトール、及びこれらの混合物からなる群から選択され、又は
クロストリジウム・パーフリンジェンスを調節する前記代謝産物が、ジホモリノール酸(20:2n6)、アラキドン酸(20:4n6)、アドレナート(22:4n6)、マンノース、3−ヒドロキシブチレート(BHBA)、トリゴネリン(N’−ニコチン酸メチル)、エイコセン酸(20:1n9又は11)、ドコサペンタエン酸(n3 DPA;22:5n3)、パルミトイルスフィンゴミエリン、グリセリン酸、リノレン酸[α又はγ;(18:3n3又は6)]、ジホモリノレン酸(20:3n3又はn6)、X−11378、X−17010、及びこれらの混合物からなる群から選択される、請求項17に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662434560P | 2016-12-15 | 2016-12-15 | |
US62/434,560 | 2016-12-15 | ||
PCT/IB2017/057848 WO2018109665A1 (en) | 2016-12-15 | 2017-12-12 | Compositions and methods that modulate bacteria in a companion animal |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2020513730A true JP2020513730A (ja) | 2020-05-21 |
Family
ID=60935914
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018561991A Pending JP2020513730A (ja) | 2016-12-15 | 2017-12-12 | コンパニオンアニマルにおける細菌を調節する組成物及び方法 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20180168196A1 (ja) |
EP (1) | EP3554254A1 (ja) |
JP (1) | JP2020513730A (ja) |
CN (1) | CN109414037A (ja) |
AU (1) | AU2017376919A1 (ja) |
BR (1) | BR112018076609B1 (ja) |
CA (1) | CA3025172C (ja) |
MX (1) | MX2018015344A (ja) |
RU (1) | RU2763296C2 (ja) |
WO (1) | WO2018109665A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018109666A1 (en) * | 2016-12-15 | 2018-06-21 | Nestec Sa | Compositions and methods that modulate cholesterol in a companion animal |
EP3554256B1 (en) * | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
EP3932484A4 (en) * | 2019-02-28 | 2022-11-30 | Morinaga Milk Industry Co., Ltd. | COMPOSITION FOR INDUCING PILI FORMATION IN A BACTERIUM OF THE GENUS BIFIDOBACTERIUM |
CN112820348B (zh) * | 2021-01-06 | 2023-04-07 | 宁夏医科大学总医院 | 一种检测血浆代谢与银屑病患者皮肤微生物区系相互作用的方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015523321A (ja) * | 2012-04-30 | 2015-08-13 | ソノマシューティカルズ・エルエルシー | シャルドネ種子製品の治療上の使用 |
WO2016108946A1 (en) * | 2014-12-29 | 2016-07-07 | Hill's Pet Nutrition, Inc. | Food composition and method of use |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3869546A (en) | 1972-12-22 | 1975-03-04 | Cutter Lab | Adjuvant compositions and medicinal mixtures comprising them |
NZ281797A (en) | 1994-02-18 | 1997-04-24 | Innovac Co | Inoculation of animals by inserting dried pelleted biological materials into the animal's ear |
CA2269078C (en) | 1996-10-16 | 2012-01-24 | Shaman Pharmaceuticals, Inc. | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
WO1999059630A1 (en) | 1998-05-15 | 1999-11-25 | University Of California Los Angeles | Type iii bordetella secretion system |
US6326364B1 (en) | 1999-02-08 | 2001-12-04 | Cedars-Sinai Medical Center | Use of 5-aminosalicylates as antimicrobial agents |
US6172040B1 (en) | 1999-05-28 | 2001-01-09 | A. Satyanarayan Naidu | Immobilized lactoferrin antimicrobial agents and the use thereof |
US20050106163A1 (en) | 1999-12-21 | 2005-05-19 | David Frederic R.M. | Compositions and vaccines containing antigen(s) of Cryptosporidium parvum and of another pathogen |
AU784557B2 (en) | 1999-12-21 | 2006-05-04 | Merial | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
SK14882002A3 (en) | 2000-04-27 | 2004-11-03 | Pfizer Prod Inc | The use of azalide antibiotic compositions for treating or preventing a bacterial or protozoal infection in mammals |
MY128159A (en) | 2000-06-30 | 2007-01-31 | Wyeth Corp | Methods and composition for oral vaccination |
EP1243273A1 (en) | 2001-03-22 | 2002-09-25 | Societe Des Produits Nestle S.A. | Composition comprising a prebiotic for decreasing infammatory process and abnormal activation of non-specific immune parameters |
US7666459B2 (en) * | 2001-09-12 | 2010-02-23 | The Procter & Gamble Company | Pet food compositions |
CA2535618A1 (en) | 2003-08-14 | 2005-02-24 | Merial Limited | Compositions and vaccines containing antigen(s) of cryptosporidium parvum and of another pathogen |
EP1758576A1 (en) | 2004-03-12 | 2007-03-07 | Christian Diehl | Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassionid-containing plant extracts |
US20050249842A1 (en) | 2004-05-08 | 2005-11-10 | Abrahamsen Jill M | Ingredient pakaging |
JP5188808B2 (ja) | 2004-11-03 | 2013-04-24 | アイリス モレキュラー ダイアグノスティクス, インコーポレイテッド | 同種の分析物検出 |
US8052971B2 (en) | 2005-11-21 | 2011-11-08 | MG Biologics | Oral use of specific antibodies for intestinal health |
JP2010531896A (ja) | 2007-06-26 | 2010-09-30 | チルドレンズ メディカル センター コーポレーション | 治療的投与のためのMetAP−2阻害剤ポリマーソーム |
KR101008480B1 (ko) | 2007-12-28 | 2011-01-14 | 원광대학교산학협력단 | 항균 활성을 갖는 오배자 추출물 또는 이로부터 분리된화합물을 유효성분으로 함유하는 조성물 |
WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
US8865865B2 (en) | 2008-10-29 | 2014-10-21 | Philipps-Universitat Marburg | N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimetic |
AU2010215065B2 (en) | 2009-02-20 | 2014-05-15 | Australian Poultry Crc Pty Limited | Live attenuated vaccines |
TWI556839B (zh) | 2009-05-06 | 2016-11-11 | 研究室護膚股份有限公司 | 包含活性劑-磷酸鈣粒子複合物之皮膚遞送組成物及其使用方法 |
CA2767910C (en) * | 2009-07-21 | 2014-07-08 | Hill's Pet Nutrition, Inc. | Companion animal nutrition system |
US10212954B2 (en) * | 2009-12-18 | 2019-02-26 | Colgate-Palmolive Company | Pet food compositions including probiotics and methods of manufacture and use thereof |
US8853269B2 (en) * | 2010-02-04 | 2014-10-07 | Copperhead Chemical Company Inc. | Composition and method for treating infections and promoting intestinal health |
US20120115798A1 (en) * | 2010-11-04 | 2012-05-10 | Stefan Patrick Massimino | Method for improving the immunity of a companion animal |
CN107625958A (zh) | 2011-05-17 | 2018-01-26 | 索利吉尼克斯公司 | 热稳定性疫苗组合物及其制备方法 |
ITRM20110475A1 (it) * | 2011-09-09 | 2013-03-10 | Probiotical Spa | Ceppi di batteri lattici e/o bifido batteri, opzionalmente addizionati di n-acetilcisteina e/o lisozima microincapsulato gastroprotetto, aventi attivita' di inibizione/riduzione della crescita di differenti biotipi di e.coli, incluso e.coli o157:h7 e |
US10501771B2 (en) * | 2011-11-08 | 2019-12-10 | The Board Of Regents Of The University Of Texas System | Methods and uses for metabolic profiling for Clostridium difficile infection |
EP2797426A1 (en) | 2011-12-29 | 2014-11-05 | Hill's Pet Nutrition, Inc. | Compositions and methods for modifying gastrointestinal flora |
WO2014036182A2 (en) * | 2012-08-29 | 2014-03-06 | California Institute Of Technology | Diagnosis and treatment of autism spectrum disorder |
CN111905104A (zh) | 2013-02-08 | 2020-11-10 | 罗达制药公司 | 治疗局部微生物感染的方法 |
US20140271815A1 (en) | 2013-03-15 | 2014-09-18 | Aryo Sorayya | Heat-and freeze-stable vaccines and methods of making and using same |
AU2015352099B2 (en) * | 2014-11-25 | 2020-08-13 | Société des Produits Nestlé S.A. | Methods and compositions for preserving lean body mass and promoting fat loss during weight loss |
-
2017
- 2017-12-12 RU RU2018146220A patent/RU2763296C2/ru active
- 2017-12-12 US US15/839,384 patent/US20180168196A1/en not_active Abandoned
- 2017-12-12 AU AU2017376919A patent/AU2017376919A1/en not_active Abandoned
- 2017-12-12 BR BR112018076609-7A patent/BR112018076609B1/pt active IP Right Grant
- 2017-12-12 CA CA3025172A patent/CA3025172C/en active Active
- 2017-12-12 JP JP2018561991A patent/JP2020513730A/ja active Pending
- 2017-12-12 EP EP17825615.2A patent/EP3554254A1/en active Pending
- 2017-12-12 CN CN201780039466.4A patent/CN109414037A/zh active Pending
- 2017-12-12 MX MX2018015344A patent/MX2018015344A/es unknown
- 2017-12-12 WO PCT/IB2017/057848 patent/WO2018109665A1/en unknown
-
2020
- 2020-03-23 US US16/826,908 patent/US11122821B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015523321A (ja) * | 2012-04-30 | 2015-08-13 | ソノマシューティカルズ・エルエルシー | シャルドネ種子製品の治療上の使用 |
WO2016108946A1 (en) * | 2014-12-29 | 2016-07-07 | Hill's Pet Nutrition, Inc. | Food composition and method of use |
Also Published As
Publication number | Publication date |
---|---|
CA3025172A1 (en) | 2018-06-21 |
CN109414037A (zh) | 2019-03-01 |
RU2018146220A (ru) | 2020-06-25 |
MX2018015344A (es) | 2019-04-29 |
US20200221736A1 (en) | 2020-07-16 |
US20180168196A1 (en) | 2018-06-21 |
CA3025172C (en) | 2024-05-28 |
EP3554254A1 (en) | 2019-10-23 |
RU2763296C2 (ru) | 2021-12-28 |
BR112018076609A2 (pt) | 2019-04-16 |
RU2018146220A3 (ja) | 2021-07-05 |
BR112018076609B1 (pt) | 2023-02-14 |
WO2018109665A1 (en) | 2018-06-21 |
AU2017376919A1 (en) | 2018-12-13 |
US11122821B2 (en) | 2021-09-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2742512C2 (ru) | Композиции и способы для модулирования микрофлоры желудочно-кишечного тракта у животного из семейства собачьих | |
US11122821B2 (en) | Compositions and methods that modulate bacteria in a companion animal | |
US11624094B2 (en) | Compositions and methods for diagnosing and treating degenerative mitral valve disease in a canine | |
RU2764558C2 (ru) | Композиции и способы, регулирующие усвояемость у животного-компаньона | |
US11806315B2 (en) | Compositions and methods for small canines | |
RU2763297C2 (ru) | Композиции и способы регуляции уровня фосфора или ферментов у животного-компаньона | |
JP7206113B2 (ja) | 小型イヌ科動物用の組成物及び方法 | |
RU2826160C2 (ru) | Композиции и способы диагностики и лечения дегенеративного заболевания митрального клапана у животного из семейства собачьих |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20190614 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20201111 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20211008 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220304 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20220405 |